	US 12,290,515 B2
	Co-crystals
Daniel G. Chain, New York, NY (US); and Ronald Mueller, Northbrook, IL (US)
Assigned to CereSpir Incorporated, New York, NY (US)
Filed by CereSpir Incorporated, New York, NY (US)
Filed on Jun. 15, 2023, as Appl. No. 18/210,217.
Application 18/210,217 is a continuation of application No. 17/973,297, filed on Oct. 25, 2022, granted, now 11,717,516.
Application 17/973,297 is a continuation of application No. 17/897,388, filed on Aug. 29, 2022.
Claims priority of provisional application 63/238,928, filed on Aug. 31, 2021.
Prior Publication US 2023/0321070 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/455 (2006.01); A61K 31/192 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/455 (2013.01) [A61K 31/192 (2013.01)]

10 Claims

1. A method of treating Alzheimer's disease in a human in need thereof, comprising administering a therapeutically effective dosage regimen of a co-crystal comprising itanapraced and nicotinamide to the human,

wherein the co-crystal has an X-ray Powder Diffraction Pattern (XRPD) with specific peaks, expressed in 2θ produced from a Cu radiation source (λ=1.54 Å after Ni filtering), at about 14.63°; 14.90°; 15.56°; 16.71°; 18.24°; 18.46°, 20.03°; 20.27°; 22.01°, 22.27°; 24.17°; 24.47°; 26.14°; 26.47°; 27.83°; 28.85°; 29.97°; 30.64°; 32.42°; 34.07°; and 39.14°, all +/−0.2 degrees 2θ.